InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2025-05-15 | Rob Bresnahan(R-PA08) | house | Sale | $1,001 - $15,000 |
| 2025-04-08 | Rob Bresnahan(R-PA08) | house | Purchase | $1,001 - $15,000 |
| 2025-02-11 | Julie Johnson(D-TX32) | house | Sale | $1,001 - $15,000 |
| 2021-09-30 | Susie Lee(D-NV03) | house | Sale | $15,001 - $50,000 |
| 2021-06-28 | Susie Lee(D-NV03) | house | Purchase | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Sales | $8.23B+7.2% | $7.68B+3.8% | $7.39B+6.5% | $6.94B+1.6% | $6.83B |
| Cost of products sold, excluding intangible asset amortization | $2.49B+13.8% | $2.19B+5.2% | $2.08B+3.2% | $2.02B+3.0% | $1.96B |
| Intangible asset amortization | $665.9M+12.5% | $591.9M+5.4% | $561.5M+6.6% | $526.8M-0.5% | $529.5M |
| Research and development | $458.5M+4.8% | $437.4M-4.6% | $458.7M+13.0% | $406.0M-6.8% | $435.8M |
| Selling, general and administrative | $3.26B+11.2% | $2.93B+3.2% | $2.84B+2.8% | $2.76B-2.9% | $2.84B |
| Restructuring and other cost reduction initiatives | $181.2M-17.3% | $219.0M+44.2% | $151.9M-20.7% | $191.6M+52.4% | $125.7M |
| Acquisition, integration, divestiture and related | $76.9M+225.8% | $23.6M+8.8% | $21.7M+90.4% | $11.4M+267.7% | $3.1M |
| Operating expenses | $7.13B+11.6% | $6.39B+4.5% | $6.12B-2.0% | $6.24B+4.6% | $5.97B |
| Operating Profit | $1.10B-14.6% | $1.29B+0.6% | $1.28B+83.5% | $696.3M-19.1% | $860.3M |
| Other income (expense), net | $25.5M+182.0% | -$31.1M-234.4% | -$9.3M | — | — |
| Interest expense, net | -$292.8M-34.3% | -$218.0M-8.3% | -$201.2M-22.1% | -$164.8M+20.9% | -$208.4M |
| Earnings before income taxes | $830.8M-19.9% | $1.04B-2.9% | $1.07B | — | — |
| Provision for income taxes | $125.7M-4.3% | $131.4M+211.4% | $42.2M | — | — |
| Net Earnings | $705.1M-22.1% | $905.2M-11.7% | $1.03B | — | — |
| Less: Net (loss) earnings attributable to noncontrolling interest | -$100K-106.7% | $1.5M+36.4% | $1.1M | — | — |
| Net Earnings of Zimmer Biomet Holdings, Inc. | $705.1M-22.0% | $903.8M-11.7% | $1.02B+342.5% | $231.4M-42.4% | $401.6M |
| Basic | $198.0M-2.5% | $203.1M-2.7% | $208.7M-0.4% | $209.6M+0.5% | $208.6M |
| Diluted | $198.7M-2.6% | $203.9M-2.8% | $209.7M-0.3% | $210.3M-0.0% | $210.4M |
| Basic | $198.0M-2.5% | $203.1M-2.7% | $208.7M-0.4% | $209.6M+0.5% | $208.6M |
| Diluted | $198.7M-2.6% | $203.9M-2.8% | $209.7M-0.3% | $210.3M-0.0% | $210.4M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
A Look At Zimmer Biomet (ZBH) Valuation After CFO Exit And Solid Quarterly Results
Stryker's Fundamentals 'Solidly Intact' Despite Cyber Disruption, RBC Says
Zimmer Biomet Supported by Sales Force Improvements, 2026 Upside Potential, RBC Says
Teva Pharmaceutical (TEVA): David Einhorn Likes This Pharma Stock